FLAG Regimen with or without Idarubicin in Children with Relapsed/Refractory Acute Leukemia: Experience from a Turkish Pediatric Hematology Center

Bengoa S. Y. , Ataseven E., Kizmazoglu D., Yenigurbuz F. , Erdem M., Oren H.

TURKISH JOURNAL OF HEMATOLOGY, cilt.34, sa.1, ss.46-51, 2017 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 34 Konu: 1
  • Basım Tarihi: 2017
  • Doi Numarası: 10.4274/tjh.2015.0411
  • Sayfa Sayıları: ss.46-51


Objective: The optimal therapy to achieve higher rates of survival in pediatric relapsed/refractory acute leukemia (AL) is still unknown. In developing countries, it is difficult to obtain some of the recent drugs for optimal therapy and mostly well-known drugs proven to be effective are used. We assessed the efficacy of the combination of fludarabine, high-dose cytarabine, and granulocyte colony-stimulating factor (FLAG regimen) with or without idarubicin (IDA) in children with relapsed/refractory acute lymphoblastic leukemia and acute myeloid leukemia.